Clinicopathological Characteristics of Everolimus-Associated Interstitial Lung Disease: A Single-Center Consecutive Analysis-Reference-Cited by-同舟云学术

Clinicopathological Characteristics of Everolimus-Associated Interstitial Lung Disease: A Single-Center Consecutive Analysis

Published:2024-04-25 Issue:2 Volume:91 Page:207-217
ISSN:1345-4676
Container-title:Journal of Nippon Medical School
language:en
Short-container-title:J Nippon Med Sch

Author:

Saito Yoshinobu¹,Terasaki Yasuhiro²,Kashiwada Takeru¹,Tanaka Toru¹,Takei Hiroyuki³,Kimura Go⁴,Kondo Yukihiro⁴,Kawagoe Tetsuro⁵,Matsushita Akira⁶,Noro Rintaro¹,Minegishi Yuji¹,Kamio Koichiro¹,Seike Masahiro¹,Gemma Akihiko¹

Affiliation:

1. Department of Pulmonary Medicine and Oncology, Nippon Medical School

2. Department of Analytic Human Pathology, Nippon Medical School

3. Department of Breast Surgery and Oncology, Nippon Medical School

4. Department of Urology, Nippon Medical School

5. Department of Gastroenterology, Nippon Medical School

6. Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School

Publisher

Medical Association of Nippon Medical School

Link

https://www.jstage.jst.go.jp/article/jnms/91/2/91_JNMS.2024_91-211/_pdf

Reference48 articles.

1. 1. Saito Y, Gemma A. Current status of DILD in molecular targeted therapies. Int J Clin Oncol. 2012 Dec;17 (6):534-41.

2. 2. White DA, Camus P, Endo M, et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med. 2010 Aug 1;182 (3):396-403.

3. 3. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010 Sep 15;116 (18):4256-65.

4. 4. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10;364 (6):514-23.

5. 5. Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011 Dec 10;378 (9808):2005-12.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Everolimus;Reactions Weekly;2024-06-15